A multiple enzyme immunoassay (multi-EIA) was developed to quantify whole-molecule human choriogonadotropin (w-hCG) and free hCG /3-subunits(hCG-13)simultaneously. A clone of a specific monoclonal antibody was coupled to solid phase; two other clones of different monoclonal antibodies were conjugated to horseradish peroxidase (HAP; EC 1.11.1.7) and alkaline phosphatase (AP; EC 3.1.3.1), respectively. These two enzyme conjugates were mixed together to measure w-hCG or hCG-/3, depending on the selection of the enzyme substrate. To measure w-hCG and hCG-/3 simultaneously, both enzyme substrates were used with the blended enzyme conjugates. The assay is simple and reproducible, and can be completed within 2 h with high specificity and sensitivity. We measured w-hCG and hCG-/3 in the sera of women with abnormal pregnancies and in patients with tumors of the reproductive system, and observed different hCG-/3-w-hCG ratios in patients with various types of trophoblastic tumors.
evaluation of gynecological patients, we obtained from the hospital laboratory serum samples from normal pregnant women and tumor patients to measure simultaneously the concentrations of w-hCG and free /3-subunits. We also evaluated the hCG-J3/w-hCG ratio.
MaterIals and Methods

w-hCG and free /3-subunit standards:
w-hCG (3326 kilo-mt. units/g) purchased from Sigma Chemical Co.
(St. Louis, MO) was further purified on a Sephadex G-150 superfine column (Pharmacia, Uppsala, Sweden) before separating the a-and 13-subunits.The hCG subunits were prepared as previously described (3), and pure subunits were identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (4). The standards of purified w-hCG and of free /3-subunits in normal serum were prepared and their contents calibrated by assay with the Amerlex-M 13-hCG kit we measured w-hCG and free /3-subunits simultaneously in every serum sample. Samples that contained high concentrations of w-hCG were appropriately diluted with zero calibrator to place them within the assay range.
Results
The monoclonal antibodies used, KW, C1OC, and C6C, were selected according to the specificities and affinities of the clones. The specificity of clone KW indicates a high affinity to both w-hCG and hCG-/3, but not to hCG-a. Clone C6C has an affinity only to hCG-/3, showing no affinity to w-hCG or hCG-a. However, clone C1OC has a high affinity not only to w-hCG and hCG-/3 but also to hCG-a (3). The fact that the clone C1OC has an affinity to both hCG-/3 and hCG-a suggests that similar epitopes may be present on the hCG-/3 and hCG-a molecule. The reproducibility of the standard curve (n = 18) was evaluated by comparing both the slope and intercept of each standard curve generated from log w-hCG concentration vs log absorbance value. The average slope was 0.82 and the average intercept was -1.65, with the coefficients of variation (CVs) being 5.2% and 5.6%, respectively. The cross-reactivity results indicate that the assay method for w-hCG measures only intact molecule hCG, with almost no effect from its a-subunit (0%), /3-subunit (1.7%), or similar glycoprotemns such as human lutropin (5.7%), human follitropin (0%), and human thyrotropin (0%) in the assay. Also, the assay method for free /3-subunits measures only free /3-subunits with no effect from intact molecules of hCG (2.3%), free a-subunits (0%), or similar glycoprotemnhormones (0%-O.5%). The ratio of hCG-/3'w-hCG could be calculated from the assay by using the resulting values for w-hCG and hCG-/3 subunits. To evaluate the multi-EIA clinically, we quantified the w-hCG and hCG-/3 values in serum specimens. As expected, we found almost no free /3-subunits in the control sera (0-4 mt. units/L) ( Table 1) Therefore, the hCG-/w-hCG ratio was about 35 to 74 times higher in choriocarcinoma than in hydatidiform or invasive moles. However, the hCG-/3/w-hCG ratios in early pregnancy were -50 times higher than ratios in normal pregnancy. This emphasizes the observation that hCG-/3Iw-hCG ratios may help in the diagnosis of choriocarcinoma as opposed to benign trophoblastic diseases, but other factors must be considered, such as the length of gestation and clinical evidence of an abnormal pregnancy.
Discussion
A previous study disclosed the specificity of hCG monoclonal antibodies (3). These monoclonal antibodies, KW, C1OC, and C6C, were selected to measure the quantity of w-hCG and free /3-subunits. KW was chosen for the coupling of solid phase because it showed an affinity to both w-hCG and hCG-/3. C6C and C1OC were chosen to prepare enzyme conjugates. C6C-AP, with its affinity only to free /3-subunits, was prepared exclusively for the hCG-/3 measurement. Therefore, the combination of KW-solid phase and C6C-AP could measure hCG-a (Figure 3) . On the other hand, C1OC-HRP was prepared to measure w-hCG. Even though clone C1OC had a similar affinity to w-hCG, free /3-, and free a-subunits, the combination of C1OC-HRP and KW-solid phase measured only w-hCG In conclusion, in the present study we have established a sensitive multi-EIA that measures, simultaneously, intact hCG and free hCG /3-subunits within 2 h by utilizing monoclonal antibodies. The quantities of w-hCG and free /3-subunits and the hCG-/3'w-hCG ratio of a serum specimen are useful in diagnosing different types of trophoblastic tumors, also taking into consideration other factors such as the length of gestation and clinical evidence of an abnormal pregnancy. All performance characteristics evaluated in the preceding pages make the multi-EIA suitable for the simple, rapid, and reliable quantification of normal and pathological w-hCG and free /3-subunit concentrations together in the serum of pregnant and gynecological tumor patients, thereby saving time and improving efficiency. We thank Drs. Seung Jo Kim and Jae Kim Chung at the Trophoblastic Disease ResearchCenter, Catholic Medical School, Seoul, Korea, for kindly supplying the serum specimens and for their clinical interpretations.
